African Countries Are Saying No to US Health Data Deals — Here's Why

African Countries Are Saying No to US Health Data Deals — Here's Why
A Kenyan court has blocked Nairobi's agreement to share health data with the United States, saying the deal doesn't protect patients' privacy well enough. This is the latest move in an ongoing dispute between the US and African governments over what Washington wants in exchange for financial aid. BBC
What the US is asking for
The US has been offering aid to African countries, but with strings attached. The deals require African governments to hand over health data, disease samples, and sometimes even information about mineral resources. WSJ Some countries have rejected these terms entirely—Ghana, Zimbabwe, and Zambia all said no. Burkina Faso accepted in February. Telegraph TRT Afrika
This split shows that governments across Africa are stuck between two competing needs: they need money now, but they're worried about protecting their sovereignty and their citizens' health later.
The main complaint: fairness
Ghana's chief concern is straightforward. Arnold Kavaarpuo, who leads Ghana's Data Protection Commission, says the US is asking for too much data without promising anything in return to protect Ghana's own interests or data. BBC
This idea of fairness—or the lack of it—has become the central complaint across the continent. Zimbabwe's government made the concern even more concrete. Officials said they see no guarantee that any new drugs or vaccines created from disease samples Africa provides would actually be available to Africans. They pointed instead to an existing United Nations system run by the World Health Organization, which already has a framework for countries to share disease samples and get access to any treatments that result. BBC
South Africa's health minister, Dr. Aaron Motsoaledi, put it most bluntly. He told the BBC that no country with self-respect should accept the US terms. He described the deal as the US getting disease samples from any outbreak in Africa, plus genetic information "for life," in exchange for five years of funding. BBC That phrase captures the core problem for critics: America gets help forever, Africa gets money only temporarily.
Dozens of civil society groups and health experts have made the same argument. They say these US terms ignore what African countries actually need or want. BBC
What the US says
The US State Department argues this is not new. A spokesperson said the data the US wants is the same basic health information that countries have shared for years to track diseases. African nations, the US notes, have already given similar data to American programs like USAID and Pepfar, a 20-year-old AIDS initiative. BBC
By this logic, the US is simply asking for what it has always gotten.
Why this matters right now
An Ebola outbreak is spreading in the Democratic Republic of Congo, a reminder of how critical speed can be in disease control. The faster scientists can share and study disease genetic code from Africa, the faster they can develop vaccines and treatments. BBC
But here's the practical reality: The debate depends on contract language that none of these governments have released publicly. Kenya's court decision suggests these deals may not hold up when examined through the lens of data protection law—a test other governments considering similar agreements are almost certainly watching. BBC
What separates these new deals from the old AIDS and disease surveillance programs, according to critics, is that they bundle health data with mining rights and don't promise Africans will actually see the drugs or vaccines that result.
The fact that Burkina Faso accepted while others rejected shows this isn't a straightforward choice for every country. Some governments have bigger funding shortages than others, or weaker legal systems to challenge a bad deal, or different foreign policy priorities. That means the debate won't be solved by one big agreement among all African nations. Instead, each country will likely make its own choice, one at a time, and the question of who owns health data and who benefits from it will keep playing out country by country.


